Clinical pharmacokinetics of (NPAz2)2NSOAz: ‘SOAz’
- 1 June 1983
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 10 (3) , 174-177
- https://doi.org/10.1007/bf00255756
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Phase i clinical trial of (NPAz2)2NSOAz: ‘SOAz’Cancer Chemotherapy and Pharmacology, 1983
- Determination of the antitumor agent SOAz (1,3,3,5,5 Pentakis(Aciridino)-1λ6,2,4,6,3λ5,5λ5 Thia-Triazadiphosphorine-1-Oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in manCancer Chemotherapy and Pharmacology, 1983
- New designs in inorganic ring systems as anticancer drugs. Antitumor activity of the aziridino (ethyleneimino) derivatives (NPAz2)2NSOX with X = F, Az, PhCancer Letters, 1981
- Clinical PharmacokineticsNew England Journal of Medicine, 1975
- Statistical estimations in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1974
- Assessment of Pharmacokinetic Constants from Postinfusion Blood Curves Obtained after I.V. InfusionJournal of Pharmaceutical Sciences, 1970